Celiprolol hydrochloride
featured

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H412551

CAS#: 57470-78-7 (HCl)

Description: Celiprolol hydrochloride is a cardioselective beta-1-adrenergic antagonist that may act as a partial agonist at some adrenergic sites.

Chemical Structure

img
Celiprolol hydrochloride
CAS# 57470-78-7 (HCl)
Instruction

Theoretical Analysis

Hodoodo Cat#: H412551
Name: Celiprolol hydrochloride
CAS#: 57470-78-7 (HCl)
Chemical Formula: C20H34ClN3O4
Exact Mass: 0.00
Molecular Weight: 415.960
Elemental Analysis: C, 57.75; H, 8.24; Cl, 8.52; N, 10.10; O, 15.39

Price and Availability

Size Price Availability Quantity
5mg USD 279 2 Weeks
25mg USD 689 2 Weeks
Bulk inquiry

Related CAS #: 56980-93-9 (free base)   57470-78-7 (HCl)  

Synonym: Celiprolol hydrochloride; Celiprolol HCl; St1396; St-1396 St 1396

IUPAC/Chemical Name: 3-(3-acetyl-4-(3-(tert-butylamino)-2-hydroxypropoxy)phenyl)-1,1-diethylurea hydrochloride

InChi Key: VKJHTUVLJYWAEY-UHFFFAOYSA-N

InChi Code: InChI=1S/C20H33N3O4.ClH/c1-7-23(8-2)19(26)22-15-9-10-18(17(11-15)14(3)24)27-13-16(25)12-21-20(4,5)6;/h9-11,16,21,25H,7-8,12-13H2,1-6H3,(H,22,26);1H

SMILES Code: CCN(C(Nc1cc(C(C)=O)c(OCC(CNC(C)(C)C)O)cc1)=O)CC.Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 415.96 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Taylor SH. Celiprolol in hypertension. Am Heart J. 1988 Nov;116(5 Pt 2):1426-34. doi: 10.1016/0002-8703(88)90135-4. PMID: 2903654.


2: Dickinson R, Horobin J. Celiprolol. Lancet. 1992 Apr 11;339(8798):940. doi: 10.1016/0140-6736(92)90990-k. PMID: 1348344.


3: Thom S, Hughes A, Schachter M, Sever P. Celiprolol. Lancet. 1992 Jan 25;339(8787):247. doi: 10.1016/0140-6736(92)90051-4. PMID: 1346201.


4: Celiprolol--a better beta blocker? Drug Ther Bull. 1992 Apr 27;30(9):35-6. PMID: 1350530.


5: Riddell JG, Shanks RG, Brogden RN. Celiprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties and its therapeutic use in hypertension and angina pectoris. Drugs. 1987 Oct;34(4):438-58. doi: 10.2165/00003495-198734040-00002. PMID: 2890513.


6: Dunn CJ, Spencer CM. Celiprolol. An evaluation of its pharmacological properties and clinical efficacy in the management of hypertension and angina pectoris. Drugs Aging. 1995 Nov;7(5):394-411. doi: 10.2165/00002512-199507050-00006. PMID: 8573993.


7: Milne RJ, Buckley MM. Celiprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in cardiovascular disease. Drugs. 1991 Jun;41(6):941-69. doi: 10.2165/00003495-199141060-00009. Erratum in: Drugs 1991 Oct;42(4):639. Erratum in: Drugs 1992 Feb;43(2):145. PMID: 1715268.


8: Lombard JN, Bonnotte B, Maynadie M, Foucher P, Reybet Degat O, Jeannin L, Camus P. Celiprolol pneumonitis. Eur Respir J. 1993 Apr;6(4):588-91. PMID: 8098286.


9: Baderkhan H, Wanhainen A, Stenborg A, Stattin EL, Björck M. Celiprolol Treatment in Patients with Vascular Ehlers-Danlos Syndrome. Eur J Vasc Endovasc Surg. 2021 Feb;61(2):326-331. doi: 10.1016/j.ejvs.2020.10.020. Epub 2020 Nov 20. PMID: 33223285.


10: Soberman JE, Frishman WH. Celiprolol in angina pectoris. Am Heart J. 1988 Nov;116(5 Pt 2):1422-5. doi: 10.1016/0002-8703(88)90134-2. PMID: 2903653.


11: Lamon KD. Safety profile of celiprolol. Am Heart J. 1988 Nov;116(5 Pt 2):1438-40. doi: 10.1016/0002-8703(88)90138-x. PMID: 2903657.


12: Nawarskas JJ, Cheng-Lai A, Frishman WH. Celiprolol: A Unique Selective Adrenoceptor Modulator. Cardiol Rev. 2017 Sep/Oct;25(5):247-253. doi: 10.1097/CRD.0000000000000159. PMID: 28742547; PMCID: PMC5549637.


13: Gorlin R. Celiprolol: introduction. Am Heart J. 1988 Nov;116(5 Pt 2):1383-4. doi: 10.1016/0002-8703(88)90127-5. PMID: 2903646.


14: Lamon KD. Evaluation of celiprolol, a new cardioselective beta 1-adrenergic blocker with vasodilating properties, in the treatment of mild to moderate hypertension in the elderly. Cardiovasc Drugs Ther. 1991 Jan;4 Suppl 6:1291-5. doi: 10.1007/BF00114236. PMID: 1672605.


15: Hunninghake DB. Effects of celiprolol and other antihypertensive agents on serum lipids and lipoproteins. Am Heart J. 1991 Feb;121(2 Pt 2):696-701. doi: 10.1016/0002-8703(91)90449-r. PMID: 1671189.


16: Kendall MJ, Rajman I. A risk-benefit assessment of celiprolol in the treatment of cardiovascular disease. Drug Saf. 1994 Mar;10(3):220-32. doi: 10.2165/00002018-199410030-00004. PMID: 7913813.


17: Parati G, Ravogli A, Bragato R, Omboni S, Mutti E, Mancia G. Clinical and hemodynamic effects of celiprolol in essential hypertension. J Cardiovasc Pharmacol. 1989;14 Suppl 7:S14-21. PMID: 2481785.


18: Galende I, Suárez JR, Azanza JR, Honorato J. Celiprolol [Celiprolol]. Rev Med Univ Navarra. 1988 Oct-Dec;32(4):229-32. Spanish. PMID: 2908736.


19: Pruss TP, Khandwala A, Wolf PS, Grebow P, Wong L. Celiprolol: a new beta adrenoceptor antagonist with novel ancillary properties. J Cardiovasc Pharmacol. 1986;8 Suppl 4:S29-32. PMID: 2427849.


20: Dubacher N, Münger J, Gorosabel MC, Crabb J, Ksiazek AA, Caspar SM, Bakker ENTP, van Bavel E, Ziegler U, Carrel T, Steinmann B, Zeisberger S, Meienberg J, Matyas G. Celiprolol but not losartan improves the biomechanical integrity of the aorta in a mouse model of vascular Ehlers-Danlos syndrome. Cardiovasc Res. 2020 Feb 1;116(2):457-465. doi: 10.1093/cvr/cvz095. PMID: 31056650.